Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 29, 9, 1, 42, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Graft Versus Host Disease (GVHD) - Overview
  3. Graft Versus Host Disease (GVHD) - Therapeutics Development
  4. Graft Versus Host Disease (GVHD) - Therapeutics Assessment
  5. Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
  6. Graft Versus Host Disease (GVHD) - Drug Profiles
  7. Graft Versus Host Disease (GVHD) - Dormant Projects
  8. Graft Versus Host Disease (GVHD) - Discontinued Products
  9. Graft Versus Host Disease (GVHD) - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • AbGenomics International Inc
  • Amgen Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cell2B Advanced Therapeutics SA
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • CSL Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Generon (Shanghai) Corp Ltd
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kymab Ltd
  • LG Chem Ltd
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • OncoImmune Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • REGiMMUNE Corp
  • Sanofi
  • Visterra Inc
  • Xenikos BV
  • XL-protein GmbH
  • Zai Lab Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rj576z/graft_versus_host?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs